Property:Results after intervention
This is a property of type Text.
M
Mazdak et al. (2012): Vitamin E reduces superficial bladder cancer recurrence: A randomized controlled Trial +
Overall:
Number in %
intervention arm: 19, control arm: 36; RR = 0.53 (95% CI 0.19 – 0.92); OR = 0.42 (95% CI: 0.19, 0.92); p = 0.04, sign.
Recurrences in the first year:
intervention arm: 66.7% of recurrences, control arm: 75% of recurrences
Time to recurrence in months (mean (SD)):
intervention arm: 9 (8.1), control arm: 8.33 (6.1); p = 0.9, not sign.
Separated by smoking status:
Smokers: intervention arm: 25%; control arm: 50%; p = 0.06
Non-smoker: intervention arm: 15.4%; control arm: 26.7%; p = 0.15 +
Meyskens et al. (1995): Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial +
'''Overall'''
No significant difference between intervention and control group for hazard ratio (p = 0.081)
''Multivariate analysis'' (controlled for age, lymphocyte percentage, absolute polymorphonuclear leukocyte count (PMN))
HR = 1.60 (95% CI: 1.05, 2.43); p = 0.014 (meaning mortality risk in control group 60% higher than in intervention group) +
Meyskens et al. (1995): Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial +
'''Overall'''
Number of side effects ≥ grade 2
- intervention group: 13/56
- control group: 3/67
- p = 0.002 +
Meyskens et al. (1995): Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial +
'''Overall'''
No significant difference between intervention and control group for hazard ratio (p = 0.11)
''Multivariate analysis'' (controlled for age, lymphocyte percentage, absolute polymorphonuclear leukocyte count (PMN))
HR = 1.53 (95% CI: 1.01, 2.31); p = 0.022 (meaning risk of progression in control group 53% higher than in intervention group) +
Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...) +
'''Overall'''
No significant differences for grade 3/4 neutropenia or death between arms (p = 0.966) +
Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...) +
'''Overall'''
No significant differences between arms (p = 0.41) +
Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...) +
'''Overall'''
No significant differences between arms regarding change since baseline (after 6 weeks p=0.399, after 3 months p=0.943);
no difference in fatigue levels on the quality of life scales (no p-value reported) +
Minchom et al. (2014): An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of (...) +
'''Overall'''
No significant differences in occurrence of nausea/vomiting (p=0.805), infections (p=0.144), diarrhea (p=0.945), constipation (p=0.572) and nephrotoxicity (p=0.516); less frequent occurrence of fatigue in intervention arm (p = 0.003) +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
No significant difference for week 6-8 post-treatment and Follow-up within a year +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
After 12 months: No significant differences between arms +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
Overall:
* Hearing dysfunction n=1 each in the intervention arm and placebo arm;
* elevated creatinine n=1 in the placebo arm;
* myelosuppression: anemia in the placebo arm n=1;
* leukopenia in the intervention arm n=3 and placebo arm n=2;
* dermatitis in the intervention arm n=2;
* dry mouth in the placebo arm n=2;
* dysgeusia in the intervention arm n=2, placebo arm n=1;
* odyno-/dysphagia in the intervention arm n=1, placebo arm n=2;
* oral/throat pain in the placebo arm n=2;
* mucus/sputum intervention arm n=3, placebo arm n=1 +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
Only one patient from the intervention arm did not reach CR and died +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
Overall: No significant differences between arms (grade 3 intervention arm 2x, placebo arm 3x, no grade 4) +
Mix et al. (2015): Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck +
After 12 months: No significant differences between arms +
Mondal et al. (2014): Comparative study among glutamine, acetyl-L-carnitine, vitamin-E and methylcobalamine for treatment of paclitaxel-induced peripheral neuropathy +
Mean (95% CI, 6 months after chemotherapy)
Sensory
Vitamin E: 1.72 (1.35, 2.10),
Vitamin B12: 1.60 (1.09, 2.11),
Carnitine: 0.65 (0.30, 1.00),
Glutamine: 0.58 (0.21, 0.95)
F-Wert (ANOVA, including values from after 3 chemotherapy cycles and after 6 chemotherapy cycles) = 1.824; p = 0.115, ns.
Post-Hoc Analysis:
Vitamin E vs. Vitamin B12: p = 0.446
Vitamin E vs. Carnitine: p < 0.001, sign.
Vitamin E vs. Glutamine: p = 0.002, sign.
No difference between Vit. E and Vit. B12, but Vit. E better progression than glutamine and ALC
Motor
Vitamin E: 1.39 (1.09, 1.69),
Vitamin B12: 1.40 (1.08, 1.72),
Carnitine: 0.20 (0.01, 0.39),
Glutamine: 0.32 (0.09, 0.55),
F(ANOVA, including values from after 3 chemotherapy cycles and after 6 chemotherapy cycles) = 2.267; p = 0.045, sign.
Post-Hoc Analysis:
Vitamin E vs. Vitamin B12: p = 0.227, ns.
Vitamin E vs. Carnitine: p < 0.001, sign.
Vitamin E vs. Glutamine: p < 0.001, sign.
No difference between Vit. E and Vit. B12, but Vit. E better progression than glutamine and ALC
Pain
Vitamin E: 1.33 (0.95, 1.71),
Vitamin B12: 1.30 (0.99, 1.61),
Carnitine: 0.10 (-0.04, 0.24),
Glutamine: 0.26 (0.05, 0.48),
F (ANOVA, including values from after 3 chemotherapy cycles and after 6 chemotherapy cycles)= 3.358; p = 0.004, sign.
Post-Hoc-Analysis:
Vitamin E vs. Vitamin B12: ns.; p = NI
Vitamin E vs. Carnitine: p < 0.001, sign.
Vitamin E vs. Glutamine: p < 0.001, sign.
No difference between Vit. E and Vit. B12, but Vit. E better progression than glutamine and ALC +
Montazeri et al. (2013): Effect of Herbal Therapy to Intensity Chemotherapy-Induced Nausea and Vomiting in Cancer Patients +
NA +
Moslemi et al. (2014): Oral zinc sulphate and prevention of radiation-induced oropharyngealmucositis in patients with head and neck cancers: A double blind, randomized controlled clinical trial +
2 weeks after end of the treatment, difference between results of intervention and placebo arm were statistically significant (p < 0.05) +
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology +
After 6 weeks post radiotherapy, levels between arms were comparable +
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology +
Median follow-up of 51 months (range 6-75): 5-year overall survival in the intervention arm was 91.9% vs. 83.1% in the control arm, no significant difference; p = 0.34 +
Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology +
Median follow-up of 49 months (range, 0-75): 5-year disease free survival in the intervention arm was 80.1% vs. 83.2% in the control arm, no significant difference; p = 0.74 +